Singular Genomics
La Jolla
About Singular Genomics
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $176.0M
- Funding stage: M&A
- Last round: Convertible Note (May 2021)
- Ticker: nasdaq:OMIC
- Website: singulargenomics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/singular-genomics-79428 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.